Alira Health

Alira Health
Senior Vice-President Global Oncology/Hematology Solutions

Raphaël G. Ognar, MSc MBA

Boston, USA

Senior Vice-President Global Oncology/Hematology Solutions, Alira Health

President, CEO & Co-Founder, NKILT Therapeutics

Pharma/Biotech executive with 24 years of commercial, drug development, product lifecycle and strategy expertise, with about 20 years in Oncology.

Throughout his career, he built extensive expertise in Oncology/Hematology and acquired leadership skills through multiple country and global roles in commercial, pipeline management and drug development, and strategy. For the last decade, he increased his focus on Immuno-Oncology and Cell Therapy technologies.

In 2018 he created ANIM8 LLC, an executive strategy and operations consulting company, where he focused essentially on supporting early-stage Biotechs, essentially in Immuno-Oncology and Cell Therapy, but also Digital Health / RWE startups.

Since Summer 2021, Raphaël founded NKILT Therapeutics and is building with his co-founders the evidence to bring a new allogeneic cell therapy concept based on an innovative binding approach.

In March 2022, he joined Alira Health, as SVP Global Oncology/Hematology and C&GT Solutions, to contribute to this fast growing and disrupting health services company, with the aim to humanize healthcare through a full spectrum of patient-centric data and tech-enabled services.

Besides fighting cancer, his passions are vintage wines, playing music in his family band, pushing himself rock climbing and traveling the world with friends and family.

Raphaël owns a Master and a D.E.A. of Physiology and Neurosciences from University of Bordeaux I&II, and an MBA in Strategic Marketing and Enterprise Management from I.A.E of Tours University.


Years in industry icon
Years in the industry

Key areas of expertise

  • Oncology/Hematology
  • Pharma/Biotech
  • Commercial
  • Drug development
  • Product lifecycle and strategy
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.